402 related articles for article (PubMed ID: 19537311)
1. Renal failure and gadolinium. The number of documented cases is rising.
Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
[No Abstract] [Full Text] [Related]
2. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
Lu CF; Hsiao CH; Tjiu JW
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
[No Abstract] [Full Text] [Related]
3. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
Jikki PN
J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
[No Abstract] [Full Text] [Related]
4. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
Stratta P; Canavese C; Quaglia M; Fenoglio R
Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
[No Abstract] [Full Text] [Related]
6. Gadolinium and systemic fibrosis: guilt by association.
Kay J; Czirják L
Ann Rheum Dis; 2010 Nov; 69(11):1895-7. PubMed ID: 20959325
[No Abstract] [Full Text] [Related]
7. Nephrogenic systemic fibrosis: history and epidemiology.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
[TBL] [Abstract][Full Text] [Related]
8. [Nephrogenic systemic fibrosis and use of MR contrast media].
Christiansen RE; Sviland L; Sekse I; Svarstad E
Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
Dawson P
J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
[No Abstract] [Full Text] [Related]
10. Focus on contrast-associated nephrogenic systemic fibrosis.
Partain CL
J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
[No Abstract] [Full Text] [Related]
11. Special issue: nephrogenic systemic fibrosis.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
[No Abstract] [Full Text] [Related]
12. Nephrogenic systemic fibrosis: the need for accurate case reporting.
Spinazzi A; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
[No Abstract] [Full Text] [Related]
13. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
Lind Ramskov K; Thomsen HS
Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
[No Abstract] [Full Text] [Related]
15. Can gadolinium be given safely to a patient on dialysis?
Rodby RA
Semin Dial; 2011; 24(4):370-1. PubMed ID: 21801214
[No Abstract] [Full Text] [Related]
16. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-induced NSF claim resolved in favor of plaintiff.
Ball JB; Samaritan G
J Med Assoc Ga; 2012; 101(3):32-3. PubMed ID: 23198628
[No Abstract] [Full Text] [Related]
19. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
